Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 09, 2007. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details an increase in the notional allocation of Ordinary Share ADRs for specific individuals following a re-valuation of the cash element of the plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b) regarding director transactions.
Important Facts for Investors
- Transaction Type: Increase in notional allocation of Ordinary Share ADRs within the US Retirement Savings Plan.
- Transaction Dates: May 3, 2007, and May 4, 2007.
- Share Prices: $57.44 per share (May 3) and $57.90 per share (May 4).
- Key Participants: Dr. JP Garnier (59 shares), Dr. R G Greig (73 shares total), Mr. D M Stout (29 shares), and others.
- Financial Data: No financial performance metrics are included in this specific filing.